ClinicalResearch
Excerpt from the Press Release: ATHENS, Ga. and LOS GATOS, Calif., June 9, 2022 /PRNewswire/ — CyanVac LLC, a clinical-stage biopharmaceutical company developing intranasal vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector, today announced preclinical data in a hamster model using CVXGA1, a COVID-19 vaccine candidate currently in Phase 1 clinical trials. The data show that CVXGA1,…
Read More
Excerpt from the Press Release: SAN DIEGO, June 2, 2022 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the acceptance of seven key oncology research abstracts authored in collaboration with Illumina at the American Society of Clinical Oncology (ASCO) annual meeting taking place June 3 – June 7…
Read More
Excerpt from the Press Release: SAN DIEGO & HOUSTON–(BUSINESS WIRE)–National Resilience, Inc. (Resilience) and The University of Texas MD Anderson Cancer Center today announced the launch of a joint venture, the Cell Therapy Manufacturing Center, to accelerate the development and manufacturing of innovative cell therapies for patients with cancer. Uniting the strengths of Resilience and…
Read More
New Preclinical Data Demonstrate Two of Vaxart’s COVID-19 Vaccine Candidates Protect Against Omicron
Results provide additional support for the cross-reactivity of Vaxart’s oral vaccine candidates Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT) today reported positive preliminary preclinical data demonstrating that two COVID-19 vaccine candidates targeting either the SARS-CoV-2 spike (S) protein for Wuhan or S protein…
Read More
-TQS-168 was well tolerated and demonstrated excellent pharmacokinetic properties- -Tranquis plans to start a Phase 2 trial in ALS by the end of 2022- Excerpt from the Press Release: REDWOOD CITY, Calif.–(BUSINESS WIRE)–Tranquis Therapeutics, Inc., a clinical stage immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases,…
Read MoreConfirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% Excerpt from the Press Release: ST. HELIER, Jersey & SHANGHAI, China & SAN FRANCISCO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some…
Read More
STI-1558, an oral SARS-CoV-2 main protease inhibitor, is specifically designed as a standalone treatment and prevention of COVID-19 without the co-administration of ritonavir as a booster for CYP3A4 inhibition. STI-1558 is also a Cathepsin L inhibitor, which may block effective viral entry into host cells without accelerating viral mutations and could work in conjunction with…
Read More
Durable responses achieved in highly refractory patients as monotherapy (one patient with relapsed squamous cell lung cancer) and in combination with pembrolizumab (several subjects with relapsed squamous cell carcinoma of the anal canal and head and neck squamous cell carcinoma) Dose escalation portion of the study has completed and recommended dose declared, as monotherapy and…
Read More
LEADER Trial Will Use Results from Foundation Medicine’s Comprehensive Genomic Profiling Tests to Screen for Actionable Driver Mutations to Inform Trial Enrollment and Targeted Therapy Options for Patients New “Trial in Progress” Abstract at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Details LEADER’s Primary Objective to Determine the Proportion of Patients Possessing Actionable…
Read More
Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% Excerpt from the Press Release: Excerpt from the Press Release: ST. HELIER, Jersey & SHANGHAI, China & SAN FRANCISCO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company working…
Read More